Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Nitric oxide signaling in health and disease
JO Lundberg, E Weitzberg - Cell, 2022 - cell.com
The surprising discovery that the diatomic gas nitric oxide (NO) is generated by mammalian
cells and serves to regulate a multitude of physiological processes has continued to …
cells and serves to regulate a multitude of physiological processes has continued to …
The functional and clinical roles of liquid biopsy in patient-derived models
Z Zhu, E Hu, H Shen, J Tan, S Zeng - Journal of Hematology & Oncology, 2023 - Springer
The liquid biopsy includes the detection of circulating tumor cells (CTCs) and CTC clusters
in blood, as well as the detection of, cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) …
in blood, as well as the detection of, cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) …
The role of nitric oxide synthase/nitric oxide in infection-related cancers: beyond antimicrobial activity
X Hu, Y Li, Y Cao, F Shi, L Shang - … et Biophysica Acta (BBA)-Reviews on …, 2024 - Elsevier
As a free radical and endogenous effector molecule, mammalian endogenous nitric oxide
(NO) is mainly derived from nitric oxide synthase (NOS) via L-arginine. NO participates in …
(NO) is mainly derived from nitric oxide synthase (NOS) via L-arginine. NO participates in …
Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs
S Pal Choudhuri, L Girard, JYS Lim, JF Wise… - Cancer …, 2024 - aacrjournals.org
Small cell lung cancer (SCLC) presents as a highly chemosensitive malignancy but acquires
cross-resistance after relapse. This transformation is nearly inevitable in patients but has …
cross-resistance after relapse. This transformation is nearly inevitable in patients but has …
Small cell lung cancer—an update on chemotherapy resistance
Q Ying, R Fan, Y Shen, B Chen, J Zhang, Q Li… - … Treatment Options in …, 2024 - Springer
Opinion Statement Compared to other types of lung cancer, small cell lung cancer (SCLC)
exhibits aggressive characteristics that promote drug resistance. Despite platinum-etoposide …
exhibits aggressive characteristics that promote drug resistance. Despite platinum-etoposide …
[HTML][HTML] Understanding the clinical use of levosimendan and perspectives on its future in oncology
E Ribeiro, N Vale - Biomolecules, 2023 - mdpi.com
Drug repurposing, also known as repositioning or reprofiling, has emerged as a promising
strategy to accelerate drug discovery and development. This approach involves identifying …
strategy to accelerate drug discovery and development. This approach involves identifying …
Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeutics
D Stehle, M Barresi, J Schulz, R Feil - Pharmacology & Therapeutics, 2023 - Elsevier
The second messenger cyclic guanosine monophosphate (cGMP) is an important regulator
of human (patho-) physiology and has emerged as an attractive drug target. Currently, cGMP …
of human (patho-) physiology and has emerged as an attractive drug target. Currently, cGMP …
Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review
Y Li, L Niu - Scientific reports, 2022 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) poses a serious threat to human health and
life. The effective prevention and treatment of COVID-19 complications have become crucial …
life. The effective prevention and treatment of COVID-19 complications have become crucial …
A novel small molecular inhibitor of DNMT1 enhances the antitumor effect of radiofrequency ablation in lung squamous cell carcinoma cells
YY Liu, CZ Ding, JL Chen, ZS Wang, B Yang… - Frontiers in …, 2022 - frontiersin.org
Radiofrequency ablation (RFA) is a relatively new and effective therapeutic strategy for
treating lung squamous cell carcinomas (LSCCs). However, RFA is rarely used in the clinic …
treating lung squamous cell carcinomas (LSCCs). However, RFA is rarely used in the clinic …
An approach for develo** a blood-based screening panel for lung cancer based on clonal hematopoietic mutations
R Anandakrishnan, R Shahidi, A Dai, V Antony… - Plos one, 2024 - journals.plos.org
Early detection can significantly reduce mortality due to lung cancer. Presented here is an
approach for develo** a blood-based screening panel based on clonal hematopoietic …
approach for develo** a blood-based screening panel based on clonal hematopoietic …